The American Diabetes Association (ADA) meeting in San Diego included the presentation of new data from Phase III trials evaluating Bristol-Myers Squibb (BMS) and AstraZeneca’s dapagliflozin, Boehringer Ingelheim and Eli Lilly’s linagliptin, and Novo Nordisk’s insulin degludec.
Stock investments ranging from Biotech, Pharmaceutical, and Medical Devices in the Healthcare Sector. Covering Clinical Trial recommendations and FDA Approvals.
Showing posts with label ADA meeting. Show all posts
Showing posts with label ADA meeting. Show all posts
6/28/11
GEN | News Highlights:Firms Report Promising Data for Type 1 and 2 Diabetes Candidates at 71st Annual ADA Meeting
Labels:
ADA meeting,
AstraZeneca,
Boehringer Ingelheim,
Bristol-Myers Squibb,
Diabetes mellitus type 1,
Eli Lilly,
Insulin,
Novo Nordisk,
type 1 diabetes,
Type 2 Diabetes
Subscribe to:
Posts (Atom)